AstraZeneca, Thermo Fisher to develop develop solid tissue and blood-based companion diagnostic for Tagrisso

A post-treatment blood test could inform future cancer therapy decisions, study shows

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Color Health unveils AI-powered language expert to enhance cancer care decision-making

Color Health announced Large Language Expert, a new AI application architecture to address challenges that prevent GenAI from becoming a trusted co-pilot in clinical decision-making.

February 28, 2025

Vol.51 No.08

In Brief

Siemens Healthineers, Ohio State Wexner Medical Center form 10-year, $105M partnership

Siemens Healthineers and The Ohio State Wexner Medical Center have expanded their existing strategic relationship to form a 10-year, $105 million value partnership to foster breakthroughs in clinical care, in addition to their longstanding research collaboration.

December 06, 2024

Vol.50 No.45

Clinical Roundup

Imfinzi + chemo shows improved EFS and OS in muscle-invasive bladder cancer

Positive results from the NIAGARA phase III trial showed Imfinzi (durvalumab)in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival and the key secondary endpoint of overall survival versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Follow-up data for Imfinzi + Imjudo shows OS benefit in unresectable HCC

Updated results from the HIMALAYA phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival benefit at five years for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.

September 20, 2024

Vol.50 No.35

In Brief

Thermo Fisher opens Oncomine Clinical Research grant; announces latest awardees

Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant, designed to support emerging research on molecular profiling in oncology and to help democratize the future of precision medicine.

September 13, 2024

Vol.50 No.34

AstraZeneca, Thermo Fisher to develop develop solid tissue and blood-based companion diagnostic for Tagrisso

YOU MAY BE INTERESTED IN

A post-treatment blood test could inform future cancer therapy decisions, study shows

Color Health unveils AI-powered language expert to enhance cancer care decision-making

Siemens Healthineers, Ohio State Wexner Medical Center form 10-year, $105M partnership

Imfinzi + chemo shows improved EFS and OS in muscle-invasive bladder cancer

Follow-up data for Imfinzi + Imjudo shows OS benefit in unresectable HCC

Thermo Fisher opens Oncomine Clinical Research grant; announces latest awardees

Renew today!

Subscriber content

Never miss an issue!

Login